Description: Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through Diagnosis, Oncology, and Preventive Medicine segments. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; online medical imaging in the fields of radiology and cardiology; oncology treatment services, such as chemotherapy, immunotherapy, radiotherapy, and brachytherapy; second opinion and genetic counselling; and diagnostic reports and genetic tests. It also provides telemedicine services, such as teleradiology, telecardiology, teleoncology, teledermatology, teleophthalmology, and teleconsultations; prevention plans for companies, which includes training plans on occupational risk prevention; Smart Data, a technological database for healthcare; and research and development services. The company was formerly known as Althia Health, S.L. and changed its name to Atrys Health, S.A. in May 2016. Atrys Health, S.A. was incorporated in 2007 and is headquartered in Madrid, Spain.
Home Page: www.atryshealth.com
Príncipe de Vergara 132
Madrid,
28002
Spain
Phone:
34 917 819 465
Officers
Name | Title |
---|---|
Mr. Santiago De Torres Sanahuja | Executive Chairman |
Ms. Isabel Lozano Fernandez | CEO & Executive Director |
Dr. Carlos Cordon-Cardo | Founder & Scientific Vice President |
Dr. Zvi Fuchs | Founder and Medical Vice President |
Mr. Jose Maria Huch Ginesta | Chief Financial Officer |
Luis Duran | Global Chief Technology Officer |
Encarna Vega | Administration Director |
Ms. Maria Marin | Head of Investor Relations |
Ms. Gabriela Camunas | General Counsel |
Pedro Salord | People Director |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 0.8119 |
Price-to-Sales TTM: | 1.1042 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 2084 |